Collection | 09 August 2018

Cancer immunotherapies

Cancer therapies that target multiple immune pathways take advantage of synergistic killing and decrease the risk of relapse.

This Collection is updated when relevant new content is published. Content appears in reverse chronological order. See all Collections from Nature Biomedical Engineering.

Research

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden

A mathematical model of the time course of tumour responses to immunotherapy predicts tumour burden and treatment sensitivity across cancer types and drug combinations.

Joseph D. Butner,
Zhihui Wang ⋯
Vittorio Cristini

Article | 4 Jan 2021 | Nature Biomedical Engineering

CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia

CAR-T cells specific for a neoantigen derived from the driver oncogene nucleophosmin display potent and specific cytotoxic activity in mouse models of human acute myeloid leukaemia.

Guozhu Xie,
Nikola A. Ivica ⋯
Jianzhu Chen

Article | 12 Oct 2020 | Nature Biomedical Engineering

Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours

A collagen-binding interleukin-12 formulation intravenously injected into mice bearing established immunologically cold mouse tumours led to marked tumour remission, particularly when combined with checkpoint-inhibitor immunotherapy.

Aslan Mansurov,
Jun Ishihara ⋯
Jeffrey A. Hubbell

Article | 13 Apr 2020 | Nature Biomedical Engineering

The expanding landscape of inflammatory cells affecting cancer therapy

This Perspective outlines the current map and known functions of populations of tumour-infiltrating myeloid cells in cancer, and discusses their implications for cancer therapy and biological research.

Ralph Weissleder &
Mikael J. Pittet

Perspective | 18 Mar 2020 | Nature Biomedical Engineering

Engineering patient-specific cancer immunotherapies

This Perspective overviews immunotherapies leveraging engineering approaches, including the design of biomaterials, delivery strategies and nanotechnology solutions, for the realization of individualized cancer treatments.

Lindsay Scheetz,
Kyung Soo Park ⋯
James J. Moon

Perspective | 12 Aug 2019 | Nature Biomedical Engineering

Traceless aptamer-mediated isolation of CD8⁺ T cells for chimeric antigen receptor T-cell therapy

DNA aptamers that specifically bind to the T-cell marker CD8 and can be displaced by a complementary oligonucleotide enable the isolation, at high purity and yield, of CD8⁺ T cells for chimeric antigen receptor T-cell therapies.

Nataly Kacherovsky,
Ian I. Cardle ⋯
Suzie H. Pun

Article | 17 Jun 2019 | Nature Biomedical Engineering

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

The physiological degradation of programmed-death ligand 1 is reduced by the palmitoylation of its intracellular domain, and this process can be inhibited to promote T-cell immunity against tumours.

Han Yao,
Jiang Lan ⋯
Jie Xu

Article | 25 Mar 2019 | Nature Biomedical Engineering

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy

The systemic administration of haematopoietic stem cells conjugated to anti-PD-1-decorated platelets in leukaemic mice promotes the delivery of the checkpoint inhibitor to the bone marrow and suppresses the growth and recurrence of leukaemia.

Quanyin Hu,
Wujin Sun ⋯
Zhen Gu

Article | 29 Oct 2018 | Nature Biomedical Engineering

Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses

The combination of systemic immune checkpoint inhibition with local administration of a hydrogel containing the enzyme catalase, a radioisotope and an immunostimulatory agent promotes effective antitumour immune responses in mice models.

Yu Chao,
Ligeng Xu ⋯
Zhuang Liu

Article | 16 Jul 2018 | Nature Biomedical Engineering

A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer

A supramolecule that inhibits the colony stimulating factor 1 and SIRPα receptors on macrophages significantly enhances antitumour and antimetastatic efficacies in two aggressive animal models of melanoma and breast cancer.

Ashish Kulkarni,
Vineethkrishna Chandrasekar ⋯
Shiladitya Sengupta

Article | 2 Jul 2018 | Nature Biomedical Engineering

Biomanufacturing for clinically advanced cell therapies

This Review discusses the manufacturing of cell products for clinically advanced cell therapies, and highlights potential manufacturing bottlenecks and solutions towards the cost-effective commercialization of the therapies.

Ayesha Aijaz,
Matthew Li ⋯
Biju Parekkadan

Review Article | 11 Jun 2018 | Nature Biomedical Engineering

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

β-Cyclodextrin nanoparticles carrying an antagonist of the toll-like receptors TLR7 and TLR8 drive the M1 phenotype in tumour-associated macrophages and improve immunotherapy response rates in tumour mouse models when used with checkpoint blockade.

Christopher B. Rodell,
Sean P. Arlauckas ⋯
Ralph Weissleder

Article | 21 May 2018 | Nature Biomedical Engineering

Programming CAR-T cells to kill cancer

This Review Article provides an overview of chimeric antigen receptors (CARs) for T cells and discusses engineering strategies for the design of next-generation CAR-T therapies for haematologic and solid cancers.

Louai Labanieh,
Robbie G. Majzner &
Crystal L. Mackall

Review Article | 11 Jun 2018 | Nature Biomedical Engineering

Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy

Combining immune checkpoint inhibition with radiotherapy–radiodynamic therapy, enabled by intratumorally injected nanoscale metal–organic frameworks, promotes systemic antitumour immunity and tumour rejection in mouse models of breast and colorectal cancer.

Kuangda Lu,
Chunbai He ⋯
Wenbin Lin

Article | 26 Mar 2018 | Nature Biomedical Engineering

Determining T-cell specificity to understand and treat disease

This Perspective discusses recent technological developments in flow cytometry and DNA sequencing that enable the interrogation of T-cell specificities in infection, cancer and autoimmunity to inform disease development and treatment.

Sine Reker Hadrup &
Evan W. Newell

Perspective | 10 Oct 2017 | Nature Biomedical Engineering

Designing nanomedicine for immuno-oncology

Drawing from recent successes in cancer immunotherapy, this Perspective discusses that effective cancer-nanomedicine therapies can be designed to prime antitumour immunity far from the site of disease.

Wen Jiang,
Christina A. von Roemeling ⋯
Betty Y. S. Kim

Perspective | 10 Feb 2017 | Nature Biomedical Engineering

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

By targeting the surgical bed and circulating tumour cells, platelets conjugated with an antibody against an immune checkpoint protein prevent tumour recurrence and metastasis following resection of the primary tumour.

Chao Wang,
Wujin Sun ⋯
Zhen Gu

Article | 23 Jan 2017 | Nature Biomedical Engineering

News & Comment

Collagen-binding IL-12 inflames ‘cold’ tumours

The intravenous administration of a formulation of interleukin-12 that binds to collagen in established ‘immunologically cold’ murine tumours enhances interferon-γ production by T cells and causes tumour remission, especially when in combination with immune checkpoint blockade therapy.

Jürgen Scheller &
Philipp A. Lang

News & Views | 14 May 2020 | Nature Biomedical Engineering

Prevention of CAR-T-cell dysfunction

The overexpression of the transcription factor c-Jun improves chimeric-antigen-receptor T-cell functionality and enhances the killing of low-antigen-expressing liquid and solid cancers in mice.

Martin W. LaFleur,
Brian C. Miller &
Arlene H. Sharpe

News & Views | 7 Jan 2020 | Nature Biomedical Engineering

Individualized treatments for the many

Broadening access to personalized medicines will require scalable and efficient manufacturing processes that help decrease production costs.

Editorial | 7 Oct 2019 | Nature Biomedical Engineering

Rewiring regulatory T cells for tumour killing

In mouse models of cancer, the inhibition of a set of regulatory proteins improves checkpoint-blockade therapy by causing regulatory T cells to produce the cytokine interferon-γ.

Tomasz Maj &
Weiping Zou

News & Views | 5 Aug 2019 | Nature Biomedical Engineering

Cell fishing with DNA aptamers

In the manufacturing of cell-based therapeutics, isolating cells via DNA aptamers is an attractive alternative to magnetic-activated cell sorting.

Yvonne Y. Chen

News & Views | 7 Oct 2019 | Nature Biomedical Engineering

Immunotherapies for autoimmune diseases

Autoimmune diseases should benefit from treatments that piggyback on the successes of cancer immunotherapies.

Editorial | 5 Apr 2019 | Nature Biomedical Engineering

Tumour suppression by blocking palmitoylation

Enhanced lysosomal degradation of the transmembrane protein programmed cell-death protein-1 ligand in tumour cells, enabled by blocking the protein’s post-translational lipid modification, promotes T-cell-mediated suppression of tumour growth in mice.

Stephane Lefrancois

News & Views | 25 Mar 2019 | Nature Biomedical Engineering

Cancer immunotherapies repurposed for use in autoimmunity

Immunotherapies developed to treat cancer can be adapted to treat autoimmunity.

Dominic A. Boardman &
Megan K. Levings

Comment | 18 Feb 2019 | Nature Biomedical Engineering

Checkpoint inhibition in the bone marrow

The coupling of blood platelets bearing anti-programmed cell death protein 1 antibodies to haematopoietic stem cells enables delivery of checkpoint-blockade therapy to bone marrow to promote T-cell-mediated control of leukaemia in mice.

Martina Seiffert

News & Views | 8 Nov 2018 | Nature Biomedical Engineering

Powerful combination therapies

Cancer therapies that target multiple biological pathways take advantage of synergistic killing, and decrease the risk of relapse.

Editorial | 9 Aug 2018 | Nature Biomedical Engineering

Combined local and systemic attacks

Intratumoral injection of a hydrogel impregnated with radioisotope-labelled catalase and an immunostimulant, along with systemic immune checkpoint blockade, inhibits tumour growth in mouse models of localized cancer and metastatic cancer.

Catherine S. Spina &
Charles G. Drake

News & Views | 9 Aug 2018 | Nature Biomedical Engineering

Instructing macrophages to fight cancer

Two drug-loaded nanoparticle formulations that preferentially accumulate within tumour-associated macrophages induce macrophage repolarization to a tumoricidal state that leads to potent antitumour activity in multiple murine models of cancer.

Heather H. Gustafson &
Suzie H. Pun

News & Views | 9 Aug 2018 | Nature Biomedical Engineering

Challenges towards the realization of individualized cancer vaccines

Bringing truly personalized cancer vaccination with tumour neoantigens to the clinic will require overcoming the challenges of optimized vaccine design, manufacturing and affordability, and identification of the most suitable clinical setting.

Özlem Türeci,
Martin Löwer ⋯
Ugur Sahin

Comment | 30 Jul 2018 | Nature Biomedical Engineering

Systemic immune effects boost radiotherapy

Nanoscale metal–organic frameworks carrying an immunotherapy payload and administered into tumours alongside a low dose of radiotherapy enhance local and systemic antitumour immunity in mouse models of breast cancer and colorectal cancer.

Wilfred Ngwa

News & Views | 9 Jul 2018 | Nature Biomedical Engineering

Towards advanced cell therapies

For cell therapies to transition from promises to products, increased efforts need to be put into the identification of the factors and biological mechanisms that affect safety and efficacy, and into the design of cost-effective methods for the harvesting, expansion, manipulation and purification of the cells.

Editorial | 11 Jun 2018 | Nature Biomedical Engineering

Towards superior dendritic-cell vaccines for cancer therapy

Potent dendritic-cell cancer vaccines could be used to induce functional antitumour immunity without off-target toxicity.

Mansi Saxena,
Sreekumar Balan ⋯
Nina Bhardwaj

Comment | 11 Jun 2018 | Nature Biomedical Engineering

Towards a personalized iPSC-based vaccine

A vaccine based on induced pluripotent stem cells mimicking the expression of tumour-cell antigens induces significant antitumour immune responses in mouse models.

Cleo Goyvaerts &
Karine Breckpot

News & Views | 10 May 2018 | Nature Biomedical Engineering

Powered and controlled T-cell production

T cells can be efficiently and controllably expanded for adoptive cell therapy in a culture system consisting of lipid bilayers bearing membrane-bound cues for the stimulation of T-cell receptors and of supporting silica microrods that release a T-cell proliferation factor.

Michael C. Milone &
Bruce L. Levine

News & Views | 7 Mar 2018 | Nature Biomedical Engineering

Cancer immunotherapy: Wound-bound checkpoint blockade

Platelets delivering the immunotherapeutic antibody anti-PD-L1 to the site of surgically removed tumours reduce cancer recurrence and metastatic spread in mice.

Morteza Mahmoudi &
Omid C. Farokhzad

News & Views | 10 Feb 2017 | Nature Biomedical Engineering

Cancer immunotherapies

Research

News & Comment

Search

Quick links